Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jamila Faiq

Nurse Practitioner San Marcos, CA Nurse Practitioner

NPI 1518414366 CMS profile 10446152

838 Nordahl Rd Ste 300, San Marcos, CA 92069

Open in the dashboard

General payments

$11,525

422 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jamila Faiq of San Marcos, CA is reported in the CMS Open Payments database as having received $11,525 across 422 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,293 132
2024 General $2,535 99
2023 General $2,953 117
2022 General $1,274 48
2021 General $1,471 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamila Faiq
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jamila Faiq were reported at $3,293. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jamila Faiq Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,471 $135 $40–$426 $132
2022 $1,274 $152 $48–$470 $149
2023 $2,953 $166 $54–$529 $160
2024 $2,535 $173 $55–$556 $164
2025 $3,293 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $2,485 56 payments
  2. Janssen Biotech, Inc. $955 28 payments
  3. Merck Sharp & Dohme Corporation $886 41 payments
  4. Gilead Sciences, Inc. $567 23 payments
  5. Pfizer Inc. $555 26 payments
  6. Pharmacyclics LLC, An AbbVie Company $456 19 payments
  7. AstraZeneca Pharmaceuticals LP $416 19 payments
  8. Regeneron Healthcare Solutions, Inc. $351 12 payments
  9. BeiGene USA, Inc. $322 13 payments
  10. AbbVie, Inc. $291 12 payments
  11. Other $4,240 173 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,595 401 payments
  2. Long term medical supply or device loan $1,631 18 payments
  3. Education $300 3 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,564 23 payments
  2. KEYTRUDA $886 41 payments
  3. IMBRUVICA $670 28 payments
  4. DARZALEX $639 15 payments
  5. BRUKINSA $409 16 payments
  6. LIBTAYO $351 12 payments
  7. TECVAYLI $330 6 payments
  8. Trodelvy $308 11 payments
  9. TALVEY $292 4 payments
  10. LYNPARZA $278 13 payments
  11. Other $7,625 339 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

98

Median for Nurse Practitioner: 389

Drug cost

$1,246

Median for Nurse Practitioner: $21,885

Branded share of claims

22.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 22 $457
Prochlorperazine Maleate Generic 23 $322
Anastrozole Generic 16 $180
Acyclovir Generic 13 $142
Methylprednisolone Generic 12 $76
Prednisone Generic 12 $68

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$15,537

Medicare's payments for the services billed

Medicare patients

41

Average age 76

Services billed

479

19 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Chronic kidney disease 39%
Cancer 37%
Arthritis 37%
Diabetes 34%
Atrial fibrillation 32%
Ischemic heart disease 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 52 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $152
$152 — —
MEKINIST
  • Novartis Pharmaceuticals Corporation $112
$112 — —
ENHERTU
  • Daiichi Sankyo Inc. $107
$107 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $105
$105 — —
IMBRUVICA
  • AbbVie, Inc. $89
  • Janssen Biotech, Inc. $7
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 52 with Patron

Records

422 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record